RNI's research presented at 14th International conference of the Inflammation Research Association
Results of RNI's latest research was presented at the 14th International conference of the Inflammation Research AssociationRNI's latest research was presented at the 14th International conference of the Inflammation Research Association. This work details the results of research on the joint health product reparagen®, derived from RNI proprietary products (Vincaria® and RNI 249). Specifically the ability of reparagen to upregulate the production of IGF-1 within human cartilage and protect cartilage from the destructive effects of inflammation. IGF-1 is a master repair factor in cartilage and is responsible for the production of new cartilage and the repair of damaged cartilage.

View the Powerpoint presentation of this research. IRA-2006.ppt ( 518K )

View the associated press release. IRArelease final.pdf ( 14k )

 

Publication of Mechanism of Action of Reparagen
RNI published, in collaboration with researchers at Case Western Reserve University Medical School and Albany Medical College, the mechanisms of action of Reparagen - its innovative treatment for joint health. The article can be downloaded for free from the publisher BMC Complementary and Alternative Medicine.

View the associated press release. Press-Release-REP-BMC.pdf ( 48k )

Adobe Reader can be downloaded from Adobe.

Previous RNI News Center articles.